Thanks again to our #CME Twitter Chat faculty!
Israh (Khan)Akhtar Swikrity U Baskota,MD, FCAP Melissa Krystel-Whittemore, MD Thaer Khoury, MD 🇸🇾 🇺🇸 ܬ̥ܰܐܐܶܪ ܟ̥ܽܘܪܺܝ
#HER2low #PathTwitter #BreastPath

LibbyMBC HER2low

ASCP Swikrity U Baskota,MD, FCAP Melissa Krystel-Whittemore, MD Ruth O'Regan A7: We have seen inter-observer, intratumoral, and temporal heterogeneity of HER2-low status in studies
#HER2low #PathTwitter #BreastPath

Great #HER2low discussion tonight Dr. Bui Pathologist🌼 Swikrity U Baskota,MD, FCAP MAMATHA CHIVUKULA,MD,FASCP Thaer Khoury, MD 🇸🇾 🇺🇸 ܬ̥ܰܐܐܶܪ ܟ̥ܽܘܪܺܝ!
👉Catch up and continue the discussion - search #HER2low
👉Claim #CME : bit.ly/guidingher2twi…
👉Learn more: bit.ly/her2low

#PathTwitter #BreastPath #MedTwitter #pathologists

Liron Pantanowitz and Mustafa Yousif propose Quantitative Image Analysis (QIA) to address difficulties with #her2low in breast cancer cases. API - pathbytes Liron Pantanowitz Michigan Pathology

Please welcome our faculty for this #CME Twitter Chat Dr. Bui Pathologist🌼 Swikrity U Baskota,MD, FCAP MAMATHA CHIVUKULA,MD,FASCP Thaer Khoury, MD 🇸🇾 🇺🇸 ܬ̥ܰܐܐܶܪ ܟ̥ܽܘܪܺܝ to discuss #HER2low breast cancer #PathTwitter #BreastPath

Today’s CME Twitter Chat will focus on “HER2-low” breast cancer. #HER2low #PathTwitter #BreastPath Get your #CME credits here bit.ly/guidingher2twi…

If you don’t have anything nice to say, say it to Whitney Cummings. Catch The OnlyFans Roast of Whitney Cummings, streaming now. 100% free. Exclusively on OFTV!

A7: The CAP guidelines on QIA of HER2 IHC were published in 2019
#HER2low #PathTwitter #BreastPath
cap.org/protocols-and-…

My favorite mood.💖

#apoki #아뽀키 #アポキ

ASCP Israh (Khan)Akhtar Melissa Krystel-Whittemore, MD Thaer Khoury, MD 🇸🇾 🇺🇸 ܬ̥ܰܐܐܶܪ ܟ̥ܽܘܪܺܝ A7: Patients who are HR+ are less likely to achieve pCR, which increases their risk of HER2+ BC recurrence
#HER2low #PathTwitter #BreastPath

ASCP Thank you #ASCP for having me. A good way of delivery the knowledge to the #pathology community on #HER2low

ASCP Israh (Khan)Akhtar Melissa Krystel-Whittemore, MD Thaer Khoury, MD 🇸🇾 🇺🇸 ܬ̥ܰܐܐܶܪ ܟ̥ܽܘܪܺܝ It was really educational and fun! I learnt a lot! #breastpath #HER2low #pathtwitter

ASCP Israh (Khan)Akhtar Melissa Krystel-Whittemore, MD Thaer Khoury, MD 🇸🇾 🇺🇸 ܬ̥ܰܐܐܶܪ ܟ̥ܽܘܪܺܝ A7: TILs are an indicator of favorable outcomes for patients with HER2+ EBC
#HER2low #PathTwitter #BreastPath

Great point! Stuart Schnitt 😄 #HER2Low #breastcancer #breastpath #USCAP23 #uscap2023 #PathTwitter

Q Synthesis LLC Swikrity U Baskota,MD, FCAP Melissa Krystel-Whittemore, MD Ruth O'Regan Pathologists need to be aware of the molecular mechanisms underlying the variable expression of HER2 in different types of breast cancers and even in different cells within the same tumor
#HER2low #PathTwitter #BreastPath

Neoadjuvant CT and ET in HR+/HER2low and HER2 0 BC promote proliferation-related and luminal biology-related genes expression downregulation, independently from HER2 status. No different pCR rates, nor EFS/OS based on HER status, as well Hospital CLÍNIC IDIBAPS Universitat de Barcelona

ASCP Swikrity U Baskota,MD, FCAP Melissa Krystel-Whittemore, MD Thaer Khoury, MD 🇸🇾 🇺🇸 ܬ̥ܰܐܐܶܪ ܟ̥ܽܘܪܺܝ A7. Her 2 positive case 3+ #HER2low #PathTwitter #BreastPath

T-30 min til tonight's ASCP #her2low #breastcancer #twitterchat with Israh (Khan)Akhtar, Swikrity U Baskota,MD, FCAP, Thaer Khoury, MD 🇸🇾 🇺🇸 ܬ̥ܰܐܐܶܪ ܟ̥ܽܘܪܺܝ, and Melissa Krystel-Whittemore, MD - can't wait! #PathTwitter #breastpath #MedTwitter

ASCP Swikrity U Baskota,MD, FCAP Melissa Krystel-Whittemore, MD Ruth O'Regan A7: The DESTINY-Breast06 study is evaluating patients who have a HER2 IHC score > 0 and <1+ expression
#HER2low #PathTwitter #BreastPath

ASCP Swikrity U Baskota,MD, FCAP Melissa Krystel-Whittemore, MD Thaer Khoury, MD 🇸🇾 🇺🇸 ܬ̥ܰܐܐܶܪ ܟ̥ܽܘܪܺܝ A7: pCR was the risk factor most closely associated with a decreased risk of HER2+ EBC recurrence-related outcomes
#HER2low #PathTwitter #BreastPath

ASCP MAMATHA CHIVUKULA,MD,FASCP Dr. Bui Pathologist🌼 Israh (Khan)Akhtar A9: Increase awareness among pathologists on the importance of appropriate assessment of HER2 scores 0, 1+ and 2+ and potential issues surrounding HER2-testing #HER2low #PathTwitter #BreastPath

Join us along with Israh (Khan)Akhtar, Swikrity U Baskota,MD, FCAP, Thaer Khoury, MD 🇸🇾 🇺🇸 ܬ̥ܰܐܐܶܪ ܟ̥ܽܘܪܺܝ, and Melissa Krystel-Whittemore, MD for our next Twitter Chat on May 18 at 8 p.m. ET to review historic & emerging trends in HER2 testing for breast cancer patients. #HER2low #PathTwitter #BreastPath

Q7: What can we learn from the quantitative image analysis (QIA) studies evaluating HER2 interpretation?

#HER2low #PathTwitter #BreastPath

Dr. Bui Pathologist🌼 Swikrity U Baskota,MD, FCAP MAMATHA CHIVUKULA,MD,FASCP Thaer Khoury, MD 🇸🇾 🇺🇸 ܬ̥ܰܐܐܶܪ ܟ̥ܽܘܪܺܝ

Woman's Roommate Helps With Her Son
Such a precious moment! Just pure love as the world should be !!!!! Credit: sarahgracehallas - tiktok.com/@sarahgracehal…?
🔸 For more inspiration and uplifting stories, please follow 👉 Epoch Inspired

LibbyMBC Antibody drug conjugates, such as Enhertu and Trodelvy, benefit those with ER+ HER2low (as you know) as well as other subtypes of bc with HER2low and other types of cancer. They had to go through the FDA approval process so the bar shouldn't be lowered in terms of safety /2

ASCP #HER2low breast cancer #CME Twitter chat happening now with Dr. Bui Pathologist🌼 Swikrity U Baskota,MD, FCAP MAMATHA CHIVUKULA,MD,FASCP Thaer Khoury, MD 🇸🇾 🇺🇸 ܬ̥ܰܐܐܶܪ ܟ̥ܽܘܪܺܝ! Follow the #HER2low hashtag to join the discussion. #PathTwitter #breastpath #MedTwitter